ClinicalTrials.gg
CompletedNCT02601976EUROPUpdated Sep 27, 2018Results posted

Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population

A Phase 4 interventional study of Peginterferon alfa-2a and Ribavirin in Hepatitis C, sponsored by Getz Pharma. Completed. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2018-09-27.

Sponsored by Getz Pharma · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies testing peginterferon alfa-2a in Hepatitis C — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C.

Enrollment
25th of 49
64 · median 64
Started
2010
with 3 others
Phase 4
17 of 49
none open now
Registered
48th of 49
by date

Among the 49 studies testing peginterferon alfa-2a in Hepatitis C, this one is the 25th largest by enrollment, is one of 4 that started in 2010, is one of 17 in phase 4, and was the 48th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 49 studies testing peginterferon alfa-2a in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing peginterferon alfa-2a in Hepatitis C as a file.
02

Study summary

Hepatitis C is a global problem, prevalent in developed as well as in the developing countries. New treatment regimens using PegInterferon in combination with ribavirin has led to improved sustained viral response rates for some genotypes. A single arm, open labeled, multicentre trial was conducted to evaluate the response rate and safety of PegInterferon alfa-2a (Unipeg®) plus ribavirin (Ribazole®) for the treatment of patients with chronic hepatitis C infection. RVR at 4 weeks, ETR at 24 weeks for genotype 3 and at 48 weeks for genotype 1 patients and SVR was determined at 24 weeks after completion of treatment. Quality of life at baseline and at follow-up visits were determined using SF-36.

Read the detailed description

A multicenter, phase IV, open labeled, single arm study was conducted. Total 110 patients were screened for recruitment. Out of which 67 subjects met the inclusion criteria, 3 failed to give the informed consent and were excluded. The final sample size of the study was 64 patients. The duration of study was August 2010 to September 2013. Peginterferon alfa-2a 180µg 20kDa (Unipeg®) solution for injection was administered as single dose sub-cutaneous once weekly for 24 weeks to patients with genotype 3 and 48 weeks in patients with genotype 1 at the site of recruitment. Ribavirin (Ribazole) orally were given in divided daily dose according to body weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg). Quality of life related Physical Component Score (PCS) \& Mental Component Score (MCS) were measured through Health-Related Quality of Life (HRQOL) Questionnaire (SF-36). The SF-36 questionnaire was completed for all patients during their evaluations before treatment, at 4 weeks, at the end of treatment and at 24 weeks after completion of treatment.

03

Conditions studied

  • Hepatitis C

Browse trials for

Keywords

  • PegInterferon alpha-2a
  • Ribavirin
  • Hepatitis C Virus
  • Sustained Virological Response
  • End of Treatment Response
  • Unipeg
  • Ribazole
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written
  2. Treatment naïve patients
  3. Serological evidence of infection by an anti-HCV antibody test
  4. HCV positive by PCR
  5. Genotype 1,2 and 3
  6. 20-28
  7. Participants were the resident of city where he /she enrolled at their respective centre
  8. No evidence of liver cirrhosis
  9. No other significant hepatic or systemic disease
  10. No evidence of hepatic encephalopathy
  11. Normal thyroid functions (By testing TSH)
  12. Adequate bone marrow, liver and renal functions test

    • Hematology: ≥1,000/mm3, count ≥100,000 mm3, ≥11.0g/dl in female and ≥ 12.0 g/dl in male
    • Blood Chemistry: Total ≤2.0mg/dl, and ALT \<3 times normal
    • >50 ml/min
    • Proteinuria: ≤ 0.5 g per 24h.
    • or partial-thromboplastin time if ≤1.5 times the .

Exclusion criteria

Exclusion Criteria:

  1. Unable to give consent
  2. Prior treatment for
  3. Co-infection with and HCV
  4. Obesity
  5. Iron overload
  6. Other Genotypes e.g. 4, 5, 6 with their sub-types
  7. Pregnant and lactating women
  8. History of medical condition associated with chronic liver disease other than CHC (e.g. hemochromatosis, hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposure)
  9. Uncontrolled Hypertension
  10. Uncontrolled Diabetes
  11. Severe Depression
  12. cardio-vascular disease
  13. Symptomatic peripheral vascular disease
  14. Oral or parenteral anticoagulants or anti agents
  15. History of systemic anti-viral therapy at least three months prior to first dose of study medication
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    PegInterferon alfa-2a and Ribavirin

    PegInterferon alfa-2a subcutaneously once weekly Ribavirin administered orally according to the body weight

    Drug: Peginterferon alfa-2a · Drug: Ribavirin

Interventions

  • PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.

    Also known as: Unipeg

  • Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

    Also known as: Ribazole

06

What researchers measure

Primary outcomes

  1. Number of Participants With Sustained Virological Response (SVR)

    To determine the SVR at 24 weeks after completion of treatment, among those who achieved ETR

    Time frame: Post treatment Week 24

  2. Number of Participants With End Treatment Response

    To determine the End Treatment Response (ETR) rate of all patients treated with PegInterferon alfa-2a plus Ribavirin

    Time frame: Upto 48 weeks

Secondary outcomes

  1. Number of Participants Who Reported Adverse Events

    To determine the number of patients treated with PegInterferon Alfa-2a plus Ribavirin who experience any adverse drug reaction. All ADR are reported as per patient information leaflet

    Time frame: Upto 48 weeks

Other outcomes

  1. Number of Participants With Rapid Virological Response (RVR)

    To evaluate the Rapid Virological Response (RVR) of all patients treated with PegInterferon Alfa-2a plus Ribavirin at 4 weeks of treatment

    Time frame: 4 weeks

  2. Mean of Physical Component Score & Mental Component Score to Determine Quality of Life

    To determine and compare the changes in quality of life (QOL) from baseline to end of the treatment. Health-Related Quality of Life (HRQOL) Questionnaire (SF-36) was used to measure the quality of life. The SF-36 is a widely used questionnaire, and consists of 36 questions measuring eight concepts: Physical Function (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Function (SF), Role Emotional (RE), and Mental Health (MH). The scoring of the SF-36 questionnaire in our study was conducted upon a 0-100 scale, with higher scores reflecting better health status.

    Time frame: Upto 48 weeks

07

Results

Posted Sep 27, 2018

Participant flow

Participant flow — Overall Study
MilestonePegInterferon Alfa-2a and Ribavirin
Started64
Completed64
Not completed0

Outcome measures

PrimaryNumber of Participants With Sustained Virological Response (SVR)

To determine the SVR at 24 weeks after completion of treatment, among those who achieved ETR

Time frame:
Post treatment Week 24
Reported as:
Count of participants · Participants
Number of Participants With Sustained Virological Response (SVR)
ParticipantsPegInterferon Alfa-2a and Ribavirin
Number of Participants With Sustained Virological Response (SVR)49
PrimaryNumber of Participants With End Treatment Response

To determine the End Treatment Response (ETR) rate of all patients treated with PegInterferon alfa-2a plus Ribavirin

Time frame:
Upto 48 weeks
Reported as:
Count of participants · Participants
Number of Participants With End Treatment Response
ParticipantsPegInterferon Alfa-2a and Ribavirin
Number of Participants With End Treatment Response56
SecondaryNumber of Participants Who Reported Adverse Events

To determine the number of patients treated with PegInterferon Alfa-2a plus Ribavirin who experience any adverse drug reaction. All ADR are reported as per patient information leaflet

Time frame:
Upto 48 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Reported Adverse Events
ParticipantsPegInterferon Alfa-2a and Ribavirin
Number of Participants Who Reported Adverse Events10
Other pre-specifiedNumber of Participants With Rapid Virological Response (RVR)

To evaluate the Rapid Virological Response (RVR) of all patients treated with PegInterferon Alfa-2a plus Ribavirin at 4 weeks of treatment

Time frame:
4 weeks
Reported as:
Count of participants · Participants
Number of Participants With Rapid Virological Response (RVR)
ParticipantsPegInterferon Alfa-2a and Ribavirin
Number of Participants With Rapid Virological Response (RVR)48
Other pre-specifiedMean of Physical Component Score & Mental Component Score to Determine Quality of Life

To determine and compare the changes in quality of life (QOL) from baseline to end of the treatment. Health-Related Quality of Life (HRQOL) Questionnaire (SF-36) was used to measure the quality of life. The SF-36 is a widely used questionnaire, and consists of 36 questions measuring eight concepts: Physical Function (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Function (SF), Role Emotional (RE), and Mental Health (MH). The scoring of the SF-36 questionnaire in our study was conducted upon a 0-100 scale, with higher scores reflecting better health status.

Time frame:
Upto 48 weeks
Reported as:
Mean · score on a scale
Mean of Physical Component Score & Mental Component Score to Determine Quality of Life
score on a scalePegInterferon Alfa-2a and Ribavirin
Physical Component Score50.62 ± 8.22
Mental Component Score54.89 ± 9.61

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PegInterferon Alfa-2a and Ribavirin10/64 (15.6%)0/64 (0%)10/64 (15.6%)
Most frequent other events
Most frequent other events
EventPegInterferon Alfa-2a and Ribavirin
Body PainGeneral disorders5/64
RashesImmune system disorders2/64
Epigastric PainGastrointestinal disorders2/64
FluGeneral disorders1/64

Baseline characteristics

Age, Customized
Age, Customized(participants)PegInterferon Alfa-2a and Ribavirin
Count35.4 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)PegInterferon Alfa-2a and Ribavirin
Count — Female28
Count — Male36
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PegInterferon Alfa-2a and Ribavirin
American Indian or Alaska Native0
Asian64
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)PegInterferon Alfa-2a and Ribavirin
Pakistan64
Number of HCV Patients confirmed through Polymerase Chain Reaction
Number of HCV Patients confirmed through Polymerase Chain Reaction(participants)PegInterferon Alfa-2a and Ribavirin
Number64
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, Gebo KA. Treatment of chronic hepatitis C: a systematic review. Hepatology. 2002 Nov;36(5 Suppl 1):S135-44. doi: 10.1053/jhep.2002.37146. PubMed 12407587 ↗
  • Abbas Z, Jeswani NL, Kakepoto GN, Islam M, Mehdi K, Jafri W. Prevalence and mode of spread of hepatitis B and C in rural Sindh, Pakistan. Trop Gastroenterol. 2008 Oct-Dec;29(4):210-6. PubMed 19323090 ↗
  • Ali SA, Donahue RM, Qureshi H, Vermund SH. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis. 2009 Jan;13(1):9-19. doi: 10.1016/j.ijid.2008.06.019. Epub 2008 Oct 2. PubMed 18835208 ↗
  • European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. No abstract available. PubMed 25911336 ↗
  • Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis. 2008 May 23;8:69. doi: 10.1186/1471-2334-8-69. PubMed 18498666 ↗
  • Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2;140(5):346-55. doi: 10.7326/0003-4819-140-5-200403020-00010. PubMed 14996676 ↗
  • Ahmad, T., R. Ahsan, and G. Saba. Evaluation of Safety and Pharmacokinetic Behavior of Unipeg® in Healthy Human Volunteers. Journal of Pharmacy and Nutrition Sciences 2014;4.3:220-227
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Sep 2012 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 6 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2015
First posted
Nov 11, 2015
Start
Aug 2010
Primary completionActual
Sep 2012
CompletionActual
Sep 2014
Results first posted
Sep 27, 2018
Last update
Sep 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02601976
Lead sponsor
Getz Pharma
Collaborators
Dimension Research
Responsible party
Sponsor
First posted
Nov 11, 2015
Start date
Aug 2010
Primary completion
Sep 2012
Completion
Sep 2014
Results posted
Sep 27, 2018
Last update
Sep 27, 2018

Study contacts

Dr. Khawar Mehdi, MD
study director · Getz Pharma Pakistan

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion